Трансплантология (Москва) (Aug 2018)

Clinical laboratory aspects of one-component immunosuppression during liver transplantation

  • M. Sh. Khubutia,
  • V. P. Nikulina,
  • M. A. Godkov,
  • V. E. Syutkin,
  • O. I. Andreitseva,
  • A. V. Chzhao

DOI
https://doi.org/10.23873/2074-0506-2009-0-2-25-31
Journal volume & issue
Vol. 0, no. 2
pp. 25 – 31

Abstract

Read online

Clinical laboratory results were analyzed in patients on one- and two-component suppression in the late period after liver transplantation.Objective: to study the impact of one-component immunosuppression with calcineurin inhibitors on clinical laboratory parameters in the late period after liver transplantation.Subjects and methods. Examinations were made in 3 groups of patients receiving various immunosuppressive therapy regimens: 1) 15 took cyclosporine; 2) 10 had tacrolimus; 3) 8 received a calcineurin inhibitor and a mycophenolic acid preparation. Their peripheral blood samples were biochemically and immunologically studied.Results. Hyperglycemia was detected in 5 (38.5%) patients receiving tacrolimus and 3 (15%) patients taking cyclosporine. Hypertension was observed in 11 (55%) patients on cyclosporine and in 3 (23%) on tacrolimus. The above complications were seen in 50% of the patients on two-component immunosuppression. Two cases of acute rejection were noted in Groups 1 (6.7%) and 3 (12.5%). The most pronounced biochemical and immunological changes were observed in the two-component immunosuppression group.Conclusion. The use of one-component immunosuppression with calcineurin inhibitors in patients after liver transplantation is effective and adequate; however, the etiology of liver cirrhosis should be taken into account on switching to one-component suppression.

Keywords